The post Global Equities Retreat on Tech Weakness, Persistent Inflation, and Slowing UK Growth: Market Analysis for December 12th, 2025 appeared first on Stock Target Advisor.

Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

FDA may expedite approval timeline for Eli Lilly's weight-loss treatment, potentially moving decision date to late March from ...

The Dow Jones and Russell 2000 hit record highs while the Nasdaq slashed early losses. Broadcom sees AI chip sales doubling.

Euro US Dollar, US Dollar Japanese Yen, Nasdaq 100, Gold Spot US Dollar. Read 's Market Analysis on Investing.com ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly released trial results for its weight-loss drug candidate, retatrutide. The data showed high rates of weight loss, ...

Plus: OpenAI gets Disney characters for Sora in billion-dollar deal; Mass ANZ redundancies trigger pay errors, bonus delays; ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...